{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:32:03Z","timestamp":1787851923373,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>Our primary objective was to estimate statewide prenatal substance exposure based on umbilical cord sampling. Our secondary objectives were to compare prevalence of prenatal substance exposure across urban, rural, and frontier regions, and to compare contemporary findings to those previously reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We performed a cross-sectional prevalence study of prenatal substance exposure, as determined by umbilical cord positivity for 49 drugs and drug metabolites, through the use of qualitative liquid chromatography-tandem mass spectrometry. All labor and delivery units in Utah (N=45) were invited to participate. Based on a 2010 study using similar methodology, we calculated that a sample size of at least 1,600 cords would have 90% power to detect 33% higher rate of umbilical cords testing positive for any substance. Deidentified umbilical cords were collected from consecutive deliveries at participating hospitals. Prevalence of prenatal substance exposure was estimated statewide and by rurality using weighted analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>From November 2020 to November 2021, 1,748 cords (urban n=988, rural n=384, frontier n=376) were collected from 37 hospitals, representing 92% of hospitals that conduct 91% of births in the state. More than 99% of cords (n=1,739) yielded results. Statewide, 9.9% (95% CI 8.1\u201311.7%) were positive for at least one substance, most commonly opioids (7.0%, 95% CI 5.5\u20138.5%), followed by cannabinoid (11-nor-9-carboxy-delta-9-tetrahydrocannabinol [THC-COOH]) (2.5%, 95% CI 1.6\u20133.4%), amphetamines (0.9%, 95% CI 0.4\u20131.5), benzodiazepines (0.5%, 95% CI 0.1\u20130.9%), alcohol (0.4%, 95% CI 0.1\u20130.7%), and cocaine (0.1%, 95% CI 0\u20130.3%). Cord positivity was similar by rurality (urban=10.3%, 95% CI 8.3\u201312.3%, rural=7.1%, 95% CI 3.5\u201310.7%, frontier=9.2%, 95% CI 6.2\u201312.2%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.31) and did not differ by substance type. Compared with a previous study, prenatal exposure to any substance (6.8 vs 9.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.01), opioids (4.7 vs 7.0% vs 4.7%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.03), amphetamines (0.1 vs 0.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.01) and THC-COOH (0.5 vs 2.5%, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) increased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Prenatal substance exposure was detected in nearly 1 in 10 births statewide.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004868","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:01:35Z","timestamp":1657281695000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Umbilical Cord Collection and Drug Testing to Estimate Prenatal Substance Exposure in Utah"],"prefix":"10.1097","volume":"140","author":[{"given":"Marcela C.","family":"Smid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Allshouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn A.","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendyl","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Buchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu","family":"Muniyappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Varner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torri D.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/AOG.0000000000003279","article-title":"Pregnancy-associated death in Utah: contribution of drug-induced deaths","volume":"133","author":"Smid","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2105\/AJPH.2018.304771","article-title":"Amphetamine- and opioid-affected births: incidence, outcomes, and costs, United States, 2004-2015","volume":"109","author":"Admon","year":"2019","journal-title":"Am J Public Health"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/AOG.0000000000003028","article-title":"Prenatal marijuana use by self-report and umbilical cord sampling in a state with marijuana legalization","volume":"133","author":"Metz","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/10550887.2020.1831137","article-title":"Drug testing in biological samples vs. maternal surveys for the detection of substance use during whole pregnancy","volume":"39","author":"Gonz\u00e1lez-Colmenero","year":"2021","journal-title":"J Addict Dis"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/sf\/soy093","article-title":"Concealment and constraint: child protective services fears and poor mothers' institutional engagement","volume":"97","author":"Fong","year":"2019","journal-title":"Social Forces"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10995-020-03110-2","article-title":"The government's involvement in prenatal drug testing may be toxic","volume":"26","author":"Nguemeni Tiako","year":"2022","journal-title":"Matern Child Health J"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jat\/bkaa118","article-title":"Patterns of neonatal co-exposure to gabapentin and commonly abused drugs observed in umbilical cord tissue","volume":"45","author":"Okoye","year":"2021","journal-title":"J Anal Toxicol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jalm\/jfaa196","article-title":"Drug positivity findings from a universal umbilical cord tissue drug analysis program in Appalachia","volume":"6","author":"Yossuck","year":"2021","journal-title":"J Appl Lab Med"},{"key":"R12-20250423","first-page":"241","article-title":"The prevalence of prenatal opioid and other drug use in Utah","volume":"30","author":"Buchi","year":"2013","journal-title":"Am J Perinatol"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jat\/29.1.54","article-title":"The detection of oxycodone in meconium specimens","volume":"29","author":"Le","year":"2005","journal-title":"J Anal Toxicol"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization\u2014United States, 1999-2014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.drugalcdep.2021.108507","article-title":"Frequency of cannabis use during pregnancy and adverse infant outcomes, by cigarette smoking status\u20148 PRAMS states, 2017","volume":"220","author":"Haight","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4939-8823-5_21","article-title":"Quantitation of ethyl-\u03b2-D-glucuronide in human umbilical cord tissue by liquid chromatography tandem mass spectrometry (LC-MS\/MS)","volume":"1872","author":"Wabuyele","year":"2019","journal-title":"Methods Mol Biol"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-8823-5_20","article-title":"Detection of in utero cannabis exposure in umbilical cord tissue by a sensitive liquid chromatography-tandem mass spectrometry method","volume":"1872","author":"Wu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1542\/peds.2013-3524","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","journal-title":"Pediatrics"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinbiochem.2016.04.007","article-title":"Development of a liquid chromatography-tandem mass spectrometry method to address the increased utilization of umbilical cord in the assessment of in utero drug exposure","volume":"49","author":"Haglock-Adler","year":"2016","journal-title":"Clin Biochem"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clinms.2019.01.002","article-title":"Detection of in utero exposure to cannabis in paired umbilical cord tissue and meconium by liquid chromatography-tandem mass spectrometry","volume":"14","author":"Jensen","year":"2019","journal-title":"Clin Mass Spectrom"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/FTD.0b013e3182a0d18c","article-title":"Detection of neonatal drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry","volume":"36","author":"Marin","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/FTD.0000000000000693","article-title":"Monitoring prenatal exposure to buprenorphine and methadone","volume":"42","author":"Di Trana","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/FTD.0000000000000719","article-title":"Testing unconventional matrices to monitor for prenatal exposure to heroin, cocaine, amphetamines, synthetic cathinones, and synthetic opioids","volume":"42","author":"Carlier","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000485","article-title":"Detection of drug-exposed newborns","volume":"40","author":"Wabuyele","year":"2018","journal-title":"Ther Drug Monit"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:02:42Z","timestamp":1745431362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004868","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"2022-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}